Aurinia Pharmaceuticals (AUPH) Enterprise Value (2018 - 2025)
Historic Enterprise Value for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to -$351.8 million.
- Aurinia Pharmaceuticals' Enterprise Value fell 87.77% to -$351.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$351.8 million, marking a year-over-year decrease of 87.77%. This contributed to the annual value of -$358.5 million for FY2024, which is 227.88% down from last year.
- Latest data reveals that Aurinia Pharmaceuticals reported Enterprise Value of -$351.8 million as of Q3 2025, which was down 87.77% from -$315.1 million recorded in Q2 2025.
- Over the past 5 years, Aurinia Pharmaceuticals' Enterprise Value peaked at -$286.4 million during Q3 2021, and registered a low of -$466.1 million during Q4 2021.
- For the 5-year period, Aurinia Pharmaceuticals' Enterprise Value averaged around -$354.4 million, with its median value being -$350.5 million (2023).
- In the last 5 years, Aurinia Pharmaceuticals' Enterprise Value surged by 2694.66% in 2021 and then crashed by 3150.98% in 2022.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Enterprise Value stood at -$466.1 million in 2021, then grew by 16.45% to -$389.4 million in 2022, then increased by 9.99% to -$350.5 million in 2023, then dropped by 2.28% to -$358.5 million in 2024, then increased by 1.86% to -$351.8 million in 2025.
- Its Enterprise Value was -$351.8 million in Q3 2025, compared to -$315.1 million in Q2 2025 and -$312.9 million in Q1 2025.